Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol.
Ray, Kausik K; Bays, Harold E; Catapano, Alberico L; Lalwani, Narendra D; Bloedon, LeAnne T; Sterling, Lulu R; Robinson, Paula L; Ballantyne, Christie M.
N Engl J Med
; 380(11): 1022-1032, 2019 03 14.
Artigo em Inglês | MEDLINE | ID: mdl-30865796
Mendelian Randomization Study of <i>ACLY</i> and Cardiovascular Disease.
Bempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase.
Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale.
Safety and efficacy of ETC-1002 in hypercholesterolaemic patients: a meta-analysis of randomised controlled trials.
Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein-cholesterol-lowering therapy for the treatment of patients with hypercholesterolemia and type 2 diabetes mellitus.
Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.
Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.
Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study.
Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab.
Hypocholesterolemic and choleretic effects of three dimethoxycinnamic acids in relation to 2,4,5-trimethoxycinnamic acid in rats fed with a high-cholesterol/cholate diet.